Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease

Abstract

Effects of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease were investigated. Eighty patients with type 2 diabetes mellitus and coronary heart disease, who were admitted and treated in Center hospital of Zibo from January 2016 to January 2017, were selected and divided into observation group (n=40) and control group (n=40) by the random number table; symptomatic and supporting therapy, including use of metformin, captopril, asprin and levocarnitine, was used in control group while rosuvastatin was adopted in observation group in addition to the symptomatic and supporting therapy. Patients in both groups were treated for a treatment cycle, namely, 3 consecutive months. After that, indexes related to blood lipid, diabetes mellitus and vascular endothelial activity, as well as variations in inflammation-associated cytokines, before and after intervention were compared; the correlation of changes in total cholesterol (TC) with those in fasting insulin (FINS), high-sensitivity C-reactive protein (hs-CRP) and endothelin-1 (ET-1), respectively, was analyzed. Among the blood lipid indexes of the patients, the levels of TC, triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) after intervention were significantly lower than those before intervention (P<0.05), while the post-intervention level of high-density lipoprotein cholesterol (HDL-C) was higher than that before intervention (P<0.05). Compared with those before intervention, the level of FINS after intervention was remarkably higher (P<0.05), while the homeostasis model assessment of insulin resistance (HOMA-IR) level after intervention was significantly lower (P<0.05). After intervention, the levels of hs-CRP and tumor necrosis factor-α (TNF-α) in the patients were obviously decreased compared with those before intervention (P<0.05). Compared with that before intervention, the ET-1 level was decreased (P<0.05), while the nitric oxide (NO) level was elevated after intervention (P<0.05). The TC level was negatively correlated with FINS level (P<0.05) but positively correlated with the levels of hs-CRP (P<0.05) and ET-1 (P<0.05). For patients with type 2 diabetes mellitus and coronary heart disease, treatment with rosuvastatin can effectively lower the level of blood lipid and regulate insulin functions; moreover, potent decrease in blood lipid level has great significance in improving the vascular endothelial functions and reducing inflammatory response levels.

Expression, Purification and Enzymatic Activity of α-1,2 Mannosidase I Derived from Trichoderma reesei in Pichia pastoris

“…In this study, patients in the hypoglycemia and hyperglycemia groups had higher levels of FBG, 2 hPG and HbA1c when comparing to their counterparts in the control group, with a lower level of FINS in serum (all P < 0.05), suggesting the damage to the function of pancreas islet, insufficient secretion of insulin, insulin resistance in type II diabetes mellitus patients with CHD, triggering increases in the blood glycemia and glycosylated hemoglobin, which could further deteriorate the functions of vascular endothelium. Ma and Bi (2019) reported that rosuvastatin raises the level of FINS in type II diabetes mellitus patients with CHD, while application of rosuvastatin shows significance in ameliorating the insulin function and resistance. Chen et al (2018) demonstrated that Telmisartan could better regulate the level of blood glucose and reduce the insulin resistance and inflammation, thus improving the vascular endothelial functions in diabetes mellitus patients with CHD.…”

Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications

“…In a clinical observation experiment to explore the effect of TXL on the coagulation and fibrinolysis function of patients with type 2 diabetes and coronary heart disease (DM-CHD), Ma, T. et al [ 198 ] randomly divided 120 patients with DM-CHD into a conventional treatment group and a conventional treatment plus TXL group, with 60 cases in each group for 2 months. The research results show that TXL can improve the coagulation fibrinolysis function of DM-CHD patients, and its mechanism may be related to the decrease in vWF, F1+2, FIB, PAI-1 levels and the increase in t-PA activity.…”